Struggling OvaScience reorganizes, stock plunges; Chugai inks €130M deal; Ironwood, Allergan report new linaclotide CR2 data
• With its fertility game plan struggling, Waltham, MA-based OvaScience says it will chop out 30% of its staff to help reduce expenses and …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
